{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:06:08Z","timestamp":1757613968362,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"DOI":"10.7759\/cureus.91625","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:55:56Z","timestamp":1757033756000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Anticancer Effects of a Complementary Peptide for Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3) With Conventional Anticancer Drugs in the Treatment of Oral Squamous Cell Carcinoma: A Pilot Study"],"prefix":"10.7759","author":[{"given":"Naoki","family":"Katase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Nishimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015, 517:576-82. 10.1038\/nature14129","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010134","article-title":"A narrative review of prognostic gene signatures in oral squamous cell carcinoma using LASSO Cox regression","volume":"13","author":"Mohd Faizal NF","year":"2025","unstructured":"Mohd Faizal NF, Shai S, Savaliya BP, Karen-Ng LP, Kumari R, Kumar R, Vincent-Chong VK. A narrative review of prognostic gene signatures in oral squamous cell carcinoma using LASSO Cox regression. Biomedicines. 2025, 13:134. 10.3390\/biomedicines13010134","journal-title":"Biomedicines"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.1009080","article-title":"Diagnostic delay of oral squamous cell carcinoma and the fear of diagnosis: a scoping review","volume":"13","author":"Mauceri R","year":"2022","unstructured":"Mauceri R, Bazzano M, Coppini M, Tozzo P, Panzarella V, Campisi G. Diagnostic delay of oral squamous cell carcinoma and the fear of diagnosis: a scoping review. Front Psychol. 2022, 13:1009080. 10.3389\/fpsyg.2022.1009080","journal-title":"Front Psychol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S283204","article-title":"Therapeutic options in unresectable oral squamous cell carcinoma: a systematic review","volume":"13","author":"Madera M","year":"2021","unstructured":"Madera M, Tirado Amador L, Leal Acosta C. Therapeutic options in unresectable oral squamous cell carcinoma: a systematic review. Cancer Manag Res. 2021, 13:6705-19. 10.2147\/CMAR.S283204","journal-title":"Cancer Manag Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006205.pub4","article-title":"Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment","volume":"12","author":"Bulsara VM","year":"2018","unstructured":"Bulsara VM, Worthington HV, Glenny AM, Clarkson JE, Conway DI, Macluskey M. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2018, 12:CD006205. 10.1002\/14651858.CD006205.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.761379","article-title":"The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma","volume":"11","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Li S, Gao L, Zhi K, Ren W. The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. Front Oncol. 2021, 11:761379. 10.3389\/fonc.2021.761379","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari S","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014, 740:364-78. 10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biology14070842","article-title":"Molecular and genetic pathogenesis of oral cancer: a basis for customized diagnosis and treatment","volume":"14","author":"Barroso L","year":"2025","unstructured":"Barroso L, Veiga P, Melo JB, Carreira IM, Ribeiro IP. Molecular and genetic pathogenesis of oral cancer: a basis for customized diagnosis and treatment. Biology (Basel). 2025, 14:842. 10.3390\/biology14070842","journal-title":"Biology (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12116","article-title":"Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor","volume":"43","author":"Dai W","year":"2014","unstructured":"Dai W, Li Y, Zhou Q, Xu Z, Sun C, Tan X, Lu L. Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor. J Oral Pathol Med. 2014, 43:250-7. 10.1111\/jop.12116","journal-title":"J Oral Pathol Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.928","article-title":"Cetuximab for the treatment of locally advanced and recurrent\/metastatic oral cancer: an investigation of distant metastasis","volume":"5","author":"Naruse T","year":"2016","unstructured":"Naruse T, Yanamoto S, Matsushita Y, et al.. Cetuximab for the treatment of locally advanced and recurrent\/metastatic oral cancer: an investigation of distant metastasis. Mol Clin Oncol. 2016, 5:246-52. 10.3892\/mco.2016.928","journal-title":"Mol Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld JD","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, et al.. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020, 6:1563-70. 10.1001\/jamaoncol.2020.2955","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003476","article-title":"Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study","volume":"9","author":"Oliva M","year":"2021","unstructured":"Oliva M, Chepeha D, Araujo DV, et al.. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021, 9:e003476. 10.1136\/jitc-2021-003476","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01068-3","article-title":"Trends in immunotherapy for oral squamous cell carcinoma","author":"Xue N","year":"2025","unstructured":"Xue N, Wang Y, Wang Z, Zeng X, Wang J, Zhang X. Trends in immunotherapy for oral squamous cell carcinoma. Cell Oncol (Dordr). 2025, 10.1007\/s13402-025-01068-3","journal-title":"Cell Oncol (Dordr)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.job.2020.01.008","article-title":"DKK3 expression and function in head and neck squamous cell carcinoma and other cancers","volume":"62","author":"Katase N","year":"2020","unstructured":"Katase N, Nagano K, Fujita S. DKK3 expression and function in head and neck squamous cell carcinoma and other cancers. J Oral Biosci. 2020, 62:9-15. 10.1016\/j.job.2020.01.008","journal-title":"J Oral Biosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181724","article-title":"The Dkk3 gene encodes a vital intracellular regulator of cell proliferation","volume":"12","author":"Leonard JL","year":"2017","unstructured":"Leonard JL, Leonard DM, Wolfe SA, et al.. The Dkk3 gene encodes a vital intracellular regulator of cell proliferation. PLoS One. 2017, 12:e0181724. 10.1371\/journal.pone.0181724","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1749","article-title":"p63-dependent Dickkopf3 expression promotes esophageal cancer cell proliferation via CKAP4","volume":"78","author":"Kajiwara C","year":"2018","unstructured":"Kajiwara C, Fumoto K, Kimura H, et al.. p63-dependent Dickkopf3 expression promotes esophageal cancer cell proliferation via CKAP4. Cancer Res. 2018, 78:6107-20. 10.1158\/0008-5472.CAN-18-1749","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3727\/096504017X14926874596386","article-title":"DKK3 overexpression increases the malignant properties of head and neck squamous cell carcinoma cells","volume":"26","author":"Katase N","year":"2018","unstructured":"Katase N, Nishimatsu SI, Yamauchi A, et al.. DKK3 overexpression increases the malignant properties of head and neck squamous cell carcinoma cells. Oncol Res. 2018, 26:45-58. 10.3727\/096504017X14926874596386","journal-title":"Oncol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4667","article-title":"DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K\/Akt and MAPK signaling pathways","volume":"54","author":"Katase N","year":"2019","unstructured":"Katase N, Nishimatsu SI, Yamauchi A, Yamamura M, Fujita S. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K\/Akt and MAPK signaling pathways. Int J Oncol. 2019, 54:1021-32. 10.3892\/ijo.2018.4667","journal-title":"Int J Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02783-9","article-title":"Establishment of anti-DKK3 peptide for the cancer control in head and neck squamous cell carcinoma (HNSCC)","volume":"22","author":"Katase N","year":"2022","unstructured":"Katase N, Nishimatsu SI, Yamauchi A, Okano S, Fujita S. Establishment of anti-DKK3 peptide for the cancer control in head and neck squamous cell carcinoma (HNSCC). Cancer Cell Int. 2022, 22:352. 10.1186\/s12935-022-02783-9","journal-title":"Cancer Cell Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6282","article-title":"Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma","volume":"12","author":"Onda M","year":"2023","unstructured":"Onda M, Ota A, Ito K, et al.. Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma. Cancer Med. 2023, 12:16416-30. 10.1002\/cam4.6282","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19020875","article-title":"Burden of oral cancer on the 10 most populous countries from 1990 to 2019: estimates from the Global Burden of Disease Study 2019","volume":"19","author":"Zhang SZ","year":"2022","unstructured":"Zhang SZ, Xie L, Shang ZJ. Burden of oral cancer on the 10 most populous countries from 1990 to 2019: estimates from the Global Burden of Disease Study 2019. Int J Environ Res Public Health. 2022, 19:875. 10.3390\/ijerph19020875","journal-title":"Int J Environ Res Public Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091444","article-title":"Comparison of weekly and triweekly cisplatin regimens in the treatment of head and neck cancer: a systematic review and meta-analysis","volume":"17","author":"Kloska SM","year":"2025","unstructured":"Kloska SM, Kloska A. Comparison of weekly and triweekly cisplatin regimens in the treatment of head and neck cancer: a systematic review and meta-analysis. Cancers (Basel). 2025, 17:1444. 10.3390\/cancers17091444","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47060452","article-title":"Early molecular diagnosis and comprehensive treatment of oral cancer","volume":"47","author":"Hsu PC","year":"2025","unstructured":"Hsu PC, Huang JH, Tsai CC, Lin YH, Kuo CY. Early molecular diagnosis and comprehensive treatment of oral cancer. Curr Issues Mol Biol. 2025, 47:452. 10.3390\/cimb47060452","journal-title":"Curr Issues Mol Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111033","article-title":"Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: a network meta-analysis of randomized studies","volume":"210","author":"Petrelli F","year":"2025","unstructured":"Petrelli F, Trevisan F, Nardone M, et al.. Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: a network meta-analysis of randomized studies. Radiother Oncol. 2025, 210:111033. 10.1016\/j.radonc.2025.111033","journal-title":"Radiother Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3727\/096504008786991594","article-title":"Deletion at Dickkopf (dkk)-3 locus (11p15.2) is related with lower lymph node metastasis and better prognosis in head and neck squamous cell carcinomas","volume":"17","author":"Katase N","year":"2008","unstructured":"Katase N, Gunduz M, Beder L, et al.. Deletion at Dickkopf (dkk)-3 locus (11p15.2) is related with lower lymph node metastasis and better prognosis in head and neck squamous cell carcinomas. Oncol Res. 2008, 17:273-82. 10.3727\/096504008786991594","journal-title":"Oncol Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26313","article-title":"Dickkopf homolog 3 (DKK3): a candidate for detection and treatment of cancers?","volume":"233","author":"Hamzehzadeh L","year":"2018","unstructured":"Hamzehzadeh L, Caraglia M, Atkin SL, Sahebkar A. Dickkopf homolog 3 (DKK3): a candidate for detection and treatment of cancers?. J Cell Physiol. 2018, 233:4595-605. 10.1002\/jcp.26313","journal-title":"J Cell Physiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jop.13540","article-title":"The involvement of epidermal growth factor receptor\/protein kinase B\u00a0signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma","volume":"53","author":"Sasabe E","year":"2024","unstructured":"Sasabe E, Tomomura A, Yamamoto T. The involvement of epidermal growth factor receptor\/protein kinase B\u00a0signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma. J Oral Pathol Med. 2024, 53:310-20. 10.1111\/jop.13540","journal-title":"J Oral Pathol Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403991-comparison-of-the-anticancer-effects-of-a-complementary-peptide-for-dickkopf-wnt-signaling-pathway-inhibitor-3-dkk3-with-conventional-anticancer-drugs-in-the-treatment-of-oral-squamous-cell-carcinoma-a-pilot-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:55:57Z","timestamp":1757033757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403991-comparison-of-the-anticancer-effects-of-a-complementary-peptide-for-dickkopf-wnt-signaling-pathway-inhibitor-3-dkk3-with-conventional-anticancer-drugs-in-the-treatment-of-oral-squamous-cell-carcinoma-a-pilot-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.91625","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}